Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

Antiviral therapy - 1 Jun 2004

Turner Dan, Schapiro Jonathan M, Brenner Bluma G, Wainberg Mark A

Abstract excerpt

Although protease inhibitors (PIs) have dramatically improved outcomes in HIV-infected patients, half still fail treatment with PI-based combination therapy. Genetic pressure from incomplete viral suppression rapidly selects for HIV variants with protease gene mutations that confer reduced susceptibility to PI drugs. A number of specific amino acid substitutions have been associated with PI resistance. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Indinavir

Share to Pyrones

Share to Ritonavir

Share to Saquinavir

Source

Identifiers

PMID: 15259893

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.PMID 15259893Read ↗

Navigating HIV-1 drug resistance: A comprehensive review of protease inhibitor efficacy and mutation dynamics.Semantic proximity Read ↗

Resistance to protease inhibitors.Semantic proximity Read ↗

Protease inhibitor resistance update: where are we now?Semantic proximity Read ↗

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.Semantic proximity Read ↗

HIV-1 protease mutations and protease inhibitor cross-resistance.Semantic proximity Read ↗

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors.Semantic proximity Read ↗

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.Semantic proximity Read ↗

Protease inhibitor resistance in HIV-infected patients: Molecular and clinical perspectivesSemantic proximity Read ↗

International perspectives on antiretroviral resistance. Resistance to protease inhibitors.Semantic proximity Read ↗

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.Semantic proximity Read ↗

Viral resistance to protease inhibitors.Semantic proximity Read ↗

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.